UK pounds sterling (). The conversion rates from into Euros (Euro) and US dollars ($) were 1 = Euro 1.4 = $1.7.
Criteria used to ensure the validity of primary studies
The validity of the primary studies was ensured by the fact that they were randomised trials. Further characteristics of the studies were not provided in this paper.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
The effectiveness evidence was derived from 5 primary studies.
Methods of combining primary studies
The primary study estimates were combined using the Mantel-Haenszel fixed-effects method.
Investigation of differences between primary studies
Results of the review
The absolute reduction in all-cause mortality with the intensive follow-up strategy relative to the conventional approach was 7% (95% confidence interval, CI: 5 -9) in the 5-trial approach and 9% (95% CI: 7 -11) in the 4-trial approach.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic analysis was the improved survival with intensive follow-up relative to the conventional method. It was calculated from the effectiveness analysis and discounted at a rate of 1.5%. The number of life-years lost and gained came from each trial, using the average life expectancy data for the UK population and taking into account the proportion of males and females, the mean ages at initial treatment, and the number of observed deaths.
Direct costs
A 6% discount rate was applied. The costs were estimated for a 5-year period. The unit costs were reported for all items, however details of resource use were not specified in this paper although full details are available in an Excel file on the website accompanying the paper abstracted. The health services included in the economic analysis were physical examination, laboratory tests, endoscopic and imaging procedures, and treatments (palliative and salvage therapies). Chemotherapy regimens were not considered. The cost/resource boundary of the study was that of the health service. The unit costs were derived using a bottom-up approach and came from Department of Health reference costs, two published studies, and the in-house financial department. Resource use was estimated using data coming from the trials, the authors' assumptions, and other published information. No individual data were available, so the distribution of censored events (deaths) was modelled using constant numbers for each 3-month period. Full attendance to follow-up was considered. The costs were expressed in 2002 prices.
